Commercial Name: ARCHITECT STAT High Sensitive Troponin-I Reagent Kit. ANVISA Registration Number: 80146501834 .. Hazard Class: III. Lots: attached list .. Lot lot affected: 2.555 units .. Number of units distributed: 1.980. 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 ABBOTT LABORATÓRIOS DO BRASIL LTDA; Abbott Ireland Diagnostics Division. 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    2023
  • 날짜
    2016-07-04
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    According to company information: Ask your laboratory to take the Required Measures below to reduce the possibility of incidences of calibration errors. A. Once alternative batch is available, return any remaining stock from the following lots of ARCHITECT STAT High Sensitive Troponin-I reagents. (List not attached notice). B. If your laboratory DOES NOT have a batch of alternative reagent available in stock and has generated a valid calibration curve, immediately request the reagent batch replenishment. Continue to use these batches and follow the QC procedures recommended in the instructions for use. These lots have high potential for calibration failures with continued use. If calibration failures are repeated, they will prevent your lab from generating patient results. Once the replacement reagent lot is received, return any remaining stock from the reagent lots according to your laboratory procedures. C. If your laboratory has a batch of available alternate reagent in stock, continue to use these reagents immediately and begin using the alternate reagent batch. Return any remaining stock of batches of reagents according to your laboratory procedures. Your local Abbott representative can assist you in providing replacement products, financial credit and / or recommended alternative solutions. All future lots will have an appropriate shelf life before delivery. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link
  • 원인
    Field action on reducing the shelf life of selected batches of architect stat high sensitive troponin-i reagents listed in table 1 of the customer release. predictive monitoring of quality assurance of architect stat high sensitive troponin-i reagent lots was initiated after the field action in january - ref .: fa21jan2016 (field action not applicable to brazil for not having a lot distributed in brazil). as a result, abbott has identified a potential for increased calibration failures before the expiration date. the root cause of this situation is under investigation for appropriate long-term corrective action.
  • 조치
    Field Action No. FA21JAN2016 Revision 02, triggered under the responsibility of Abott. Classification of risk: III Classification of the field action: Field action - Change of validity d)

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    ANVSANVISA